Journal of Pharmaceutical Care & Health Systems
Open Access

PERK inhibition reduces hyperphosphorylated tau and rescues neuronal function in an eIF2α- independent mechanism

8^th Annual Pharma Middle East Congress

October 10-12, 2016 Dubai, UAE

Jose F Abisambra

University of Kentucky, USA

Posters & Accepted Abstracts: J Pharma Care Health Sys

Abstract :

Tauopathies are a group of more than twenty known debilitating neurodegenerative disorders that affect nearly eight million people in the United States. Currently, there is no cure for tauopathies, and there are temporary and limited benefits to current therapeutic strategies. The endoplasmic reticulum (ER) stress sensor PERK (protein kinase R-like ER kinase) has been identified as a participant in the pathogenesis and progression of tauopathies. However, the mechanism by which the PERK pathway causes neuronal dysfunction is still unknown. In this study, we treated rTg4510 tau transgenic mice at a stage when tau pathology is rampant and cognitive function is impaired with a novel and potent PERK inhibitor. The treatment significantly reduced hyperphosphorylated tau species and led to improvement of neuronal function, as determined with a sensitive and innovative imaging technique called manganese-enhanced magnetic resonance imaging (MEMRI) with quantitative R1 mapping. We also found that PERK inhibition mediated these improvements via a pathway that is independent of eIF2�?±. Our results show a novel mechanism of PERK-mediated tau phosphorylation that potentiates pathogenesis and progression of tau pathology. Future efforts aim to delineate the mechanism ruling the tau-PERK relationship. Finally, this study suggests that PERK is a viable therapeutic target to ameliorate neuronal function in tauopathies.

Biography :

Email: joe.abisambra@uky.edu